These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33258745)

  • 1. Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma.
    Tsai LL; Bhatt RS; Strob MF; Jegede OA; Sun MRM; Alsop DC; Catalano P; McDermott D; Robson PM; Atkins MB; Pedrosa I
    Radiology; 2021 Feb; 298(2):332-340. PubMed ID: 33258745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
    J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
    Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
    J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
    Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
    J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
    Mouillet G; Fritzsch J; Paget-Bailly S; Pozet A; Es-Saad I; Meurisse A; Vernerey D; Mouyabi K; Berthod D; Bonnetain F; Anota A; Thiery-Vuillemin A
    Health Qual Life Outcomes; 2019 Feb; 17(1):25. PubMed ID: 30717745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
    Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience.
    Ekenel M; Karabulut S; Cil I; Zırtıloglu A; Aydın E; Tural D
    Actas Urol Esp (Engl Ed); 2020; 44(1):27-33. PubMed ID: 31744648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
    Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
    BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
    Del Re M; Crucitta S; Brighi N; Kinspergher S; Mercinelli C; Rizzo M; Conteduca V; Rebuzzi SE; Beninato T; Venturi G; Doni L; Verzoni E; Puglisi S; Landriscina M; Porta C; Manfredi F; Caffo O; De Giorgi U; Fogli S; Danesi R
    Clin Genitourin Cancer; 2024 Oct; 22(5):102147. PubMed ID: 39030142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
    Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
    J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
    Vitruk Yu V; Semko SL; Voylenko OA; Pikul MV; Borikun TV; Zadvornyi TV; Yalovenko TM; Stakhovsky EO; Rossylna OV
    Exp Oncol; 2021 Jun; 43(2):98-103. PubMed ID: 34190510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
    Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.